EUCTR2012-000946-37-DE进行中（未招募）不适用
A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atopic dermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients aged 18 years or older
- •2. Chronic Atopic Dermatitis for at least 2 years
- •3. Patients must be applying an additive-free, basic bland emollient twice daily for at least 7 days before the baseline visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 3
排除标准
- •1. Prior treatment with REGN668
- •2. Hypersensitivity to corticosteroids or to any other ingredients contained by the TCS product used in the study
- •3. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
- •4. Known history of human immunodeficiency virus (HIV) infection
- •5. History of clinical parasite infection
- •6. Pregnant or breast-feeding women
- •7. History of alcohol or drug abuse within 2 years of the screening visit
- •8. Treatment with an investigational drug within 8 weeks or within 5 half-lives, if known (whichever is longer), before the baseline visit
- •9. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks before the baseline visit
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer paicancer painMedDRA version: 14.1Level: LLTClassification code 10069398Term: Breakthrough cancer painSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2011-002557-56-BEsanofi-aventis180
进行中（未招募）
不适用
A clinical trial to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain.cancer painMedDRA version: 14.1Level: LLTClassification code 10069398Term: Breakthrough cancer painSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2011-002557-56-HUsanofi-aventis180
进行中（未招募）
不适用
A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who have failed previous tumor necrosis factor-alpha (TNF-alpha) antagonists. - NDactive rheumatoid arthritisMedDRA version: 9.1Level: LLTClassification code 10039073EUCTR2010-021020-94-ITSanofi-aventis Recherche & D?veloppement250
进行中（未招募）
不适用
A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily (breakfast and lunch) at a dose of 300, 600 and 1200 mg or once daily (breakfast) at a dose of 1200 mg, in patients with type 2 diabetes treated with metformin and not adequately controlledEUCTR2006-001843-74-BEsanofi-aventis recherche & développement300
进行中（未招募）
不适用
A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily breakfast and lunch at a dose of 300, 600 and 1200 mg or once daily breakfast at a dose of 1200 mg, in patients with type 2 diabetes treated with metformin and not adequately controlled - NDTYPE II DIABETISMedDRA version: 8.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentEUCTR2006-001843-74-ITSanofi-Synthelabo Recherche300